Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Sales | 41,465 | 44,302 | 37,924 | -2,787 | 40,264 |
| Cost of Goods | 16,521 | 15,330 | 15,081 | -6,562 | 17,485 |
| Gross Profit | 24,944 | 28,972 | 22,843 | 3,775 | 22,779 |
| Operating Expenses | 33,139 | 32,933 | 35,477 | -13,190 | 29,062 |
| Operating Income | -7,674 | -3,631 | -12,553 | 16,403 | -5,798 |
| Other Income | 635 | 561 | 539 | 276 | 436 |
| Pre-tax Income | -7,039 | -3,070 | -12,014 | 16,679 | -5,362 |
| Income Tax | -463 | -329 | -1,664 | 4,528 | -1,187 |
| Net Income Continuous | -6,576 | -2,741 | -10,350 | 12,151 | -4,175 |
| Net Income | $-6,576 | $-2,741 | $-10,350 | $-4,908 | $-4,175 |
| EPS Basic Total Ops | -0.45 | -0.19 | -0.71 | -0.33 | -0.29 |
| EPS Basic Continuous Ops | -0.45 | -0.19 | -0.71 | 0.83 | -0.29 |
| EPS Diluted Total Ops | -0.45 | -0.19 | -0.71 | -0.33 | -0.29 |
| EPS Diluted Continuous Ops | -0.45 | -0.19 | -0.71 | 0.83 | -0.29 |
| EBITDA(a) | $-4,132 | $-81 | $-9,002 | $20,069 | $-2,303 |